Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Importance of Screening for HCC in HBV: Patient and Physician Sharing Session #7

In this episode in our series of sharing sessions between a physician and patient, Ming-Lung Yu, MD, PhD, and his patient, who is living with chronic hepatitis B, discuss the importance of screening for HCC even when HBeAg negative without overt ALT elevation.
Ming-Lung Yu, MD, PhD
Released: April 12, 2022

In episode 7 of a series of sharing sessions between a physician and patient, Ming-Lung Yu, MD, PhD, and his patient, who is living with chronic hepatitis B, discuss:

  • Role of family history in risk of hepatocellular carcinoma (HCC)
  • Surveillance for HCC
  • Steps to take when diagnosed with HCC
  • How to live a healthy life after HCC diagnosis and treatment

Information on this Educational Activity

Faculty

Ming-Lung Yu, MD, PhD

Chair Professor
Hepatobiliary Division
Department of Internal Medicine and Hepatitis Center
Kaohsiung Medical University
Visiting Staff
Hepatobiliary Division
Department of Internal Medicine
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan

Ming-Lung Yu, MD, PhD, has disclosed that he has received funds for research support from Abbott, Bristol-Myers Squibb, Gilead Sciences, and Merck; consulting fee sform AbbVie, Abbott, Ascletis, Bristol-Myers Squibb, Gilead Sciences, Merck, and Roche; and fees for non-CME/CE services from AbbVie, Abbott, Bristol-Myers Squibb, Gilead Sciences, Ipsen, and Merck.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from:
Gilead Sciences, Inc.

Related Content

Prof George Lau: proactive monitoring and treatment are necessary for all patients with CHB, regardless of age, from Clinical Care Options (CCO)

George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA) Released: December 1, 2022

Expert summaries of AASLD, EASL, APASL guidance on monitoring and treating chronic hepatitis B and delta infections, with Maria Buti, Paul Kwo, Grace Wong

Maria Buti, MD Paul Y. Kwo, MD Grace LH Wong, MD Released: December 1, 2022

Expert summaries of AASLD, EASL, and APASL guidance on monitoring and treating chronic hepatitis B and delta viral infections, from Clinical Care Options (CCO)

Maria Buti, MD Paul Y. Kwo, MD Grace LH Wong, MD Released: December 1, 2022

Professor Graham Foster shares his approach to the management of hepatitis B in older adults, from Clinical Care Options (CCO)

Graham R. Foster, FRCP, PhD Released: November 18, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings